RxDoctor Payments Data

Jordyn Brackett

Psychiatric/Mental Health · Evansville, INNPI 1548037534

Payments from drug & device makers

$815in general payments, 2019–2025

Across 28 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207
  • Ironshore Pharmaceuticals Inc.$150
  • Alkermes, Inc.$146
  • Otsuka America Pharmaceutical, Inc.$87
  • Johnson & Johnson$82
  • E.r. Squibb & Sons, L.L.C.$65
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815 in reported general payments places this provider in the 55th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$68,259
Medicare patients
195
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole84$62,587
VraylarCariprazine Hcl37$54,051
Atomoxetine Hcl17$3,623
Buspirone Hcl166$2,886
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$2,641
Duloxetine Hcl47$2,451
Lurasidone Hcl19$1,422
Hydroxyzine Hcl70$1,339
Trazodone Hcl132$1,297
Memantine Hcl49$1,244
Sertraline Hcl198$1,171
Aripiprazole14$1,094
Olanzapine46$995
Clonazepam84$988
Quetiapine Fumarate74$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$87$62,58784 claims
AbbVieVraylar$207$54,05137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →